Gordana Kosutic is the new vice president for clinical and regulatory affairs at Tranzyme Pharma.
Kosutic, an MD, has more than 25 years of experience in clinical research, medical and regulatory affairs and medical marketing. Before joining Tranzyme, she worked for Fulcrum Pharma Developments, Nobex, ClinTrials and ICN Pharmaceuticals.
Tranzyme is developing orally deliverable therapeutics for the treatment of gastrointestinal diseases. Its lead product, TZP-101, is expected to enter clinical trials in the first quarter of 2006.
“Dr. Kosutic’s appointment plays a significant role in building Tranzyme Pharma’s senior management team as we move forward in the development of TZP-101,” said Vipin Garg, Tranzyme’s chief executive officer. “Dr. Kosutic’s experience will enhance the development of our products and facilitate the strategic expansion of our therapeutic pipeline. Her impressive background will prove to be extremely valuable in not only implementing our clinical strategy but also in contributing to our business strategy.”
Tranzyme:: www.tranzyme.com
